Table 1.
Summary of the study sample. Cancer progression is defined as a competing event from any of the following events during the 12-year follow-up after the primary tumor surgery: lung cancer recurrence, metastasis, or lung cancer-related death.
| No Progression N = 128 |
Progression N = 54 |
p 1 | ||
|---|---|---|---|---|
| Cancers diagnosed 6 months after the last LDCT screening date | 27 | 21 | 0.0167 | |
| Lung cancer-related death | 0 | 45 | ||
| Age at surgery | 64.7 ± 4.9 | 65.9 ± 4.8 | 0.1067 | |
| Female, N (%) | 58 (45%) | 24 (44%) | 1.0 | |
| Smoke pack-years | 66 ± 29 | 72 ± 41 | 0.2889 | |
| Days from the last LDCT screening to the date of lung surgery | 177 ± 210 | 267 ± 299 | 0.0468 | |
| Surgery type | Sublobar resection Lobectomy |
21 107 |
8 46 |
1.0 |
| Lymphadenectomy | N (%) | 115 (90%) | 49 (91%) | 1.0 |
| Residual disease after surgery | R0 | 124 | 53 | 1.0 |
| R1 | 4 | 1 | ||
| Surgically removed lesion size (mm) | 19.7 ± 13.9 | 20.6 ± 12.6 | 0.6713 | |
| Largest invasive tumor size (mm) | 11.4 ± 6.8 | 12.9 ± 6.4 | 0.1604 | |
| Pathological cancer stage (TNM, 8th edition) | IA1 (T1a) | 50 | 19 | |
| IA1 (T1b) | 63 | 30 | 1.0 | |
| IA1 (T1c) | 15 | 5 | ||
| Highest tumor grade from all the ROIs | 1 = well-differentiated | 34 | 4 | 0.0163 |
| 2 = moderately differentiated | 53 | 30 | ||
| 3 = poorly differentiated | 35 | 14 | ||
| 4 = undifferentiated | 5 | 4 | ||
| Undetermined (GX) | 1 | 2 |
1 Two-sample t-test was used for continuous variables, and Fisher’s exact test was used for categorical variables. All tests were two-sided.